Also known as REGN1033
An anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.
Research refreshed
Trevogrumab is a monoclonal antibody from Regeneron that neutralizes mature myostatin. After an earlier life in sarcopenia research, it has re-emerged squarely in the GLP-1 era: as a muscle-sparing add-on to incretin weight-loss drugs, and as one leg of a triple combination designed to maximize fat loss while protecting muscle.
Trevogrumab is the clearest worked example of the muscle-preservation thesis. Interim results from the Phase 2 COURAGE trial — presented at EASD in 2026 — found that roughly 35% of the weight lost on semaglutide alone was lean mass, and that adding trevogrumab preserved an estimated 50–80% of that otherwise-lost lean tissue while shifting more of the loss onto fat. The triple combination of semaglutide + trevogrumab + garetosmab (an anti-activin-A antibody) went furthest, preserving about 80.9% of the lean mass semaglutide alone would have cost — the most favorable body-composition profile of the arms — though the triplet came with a substantially higher rate of tolerability-driven discontinuations, the honest trade-off in the data.
It is a monoclonal antibody (~150 kDa) and an investigational agent. Its inclusion rounds out the myostatin axis with a mature-myostatin neutralizer, complementing apitegromab’s precursor-selective approach.
Binds and neutralizes mature myostatin (GDF-8), removing its brake on muscle growth via the ActRIIB/Smad pathway. Used to offset the lean-mass loss that accompanies large GLP-1-driven weight loss.
Behind every vial of Trevogrumab is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Trevogrumab, specifically, is brought into being.
On paper, Trevogrumab weighs in at roughly 150,000 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Trevogrumab is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Trevogrumab plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Trevogrumab proves itself: identity confirmed by mass spectrometry against its ~150,000 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Trevogrumab — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Trevogrumab is a recombinant monoclonal antibody (~150 kDa) made in mammalian cell culture, characterized with antibody-grade analytics (glycan/charge-variant profiling, mass spectrometry, binding/potency bioassay) — not a synthetic peptide.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Trevogrumab, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A Regeneron monoclonal antibody that neutralizes myostatin, studied as a muscle-sparing add-on to GLP-1 weight-loss drugs and in a triple combination with semaglutide and garetosmab.
In the Phase 2 COURAGE trial, about 35% of semaglutide-alone weight loss was lean mass; adding trevogrumab preserved an estimated 50–80% of that lean tissue while shifting more of the loss onto fat — the core "quality of weight loss" idea.
No — this is a research and educational reference. Trevogrumab is an investigational antibody, not an approved drug.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.